About this trial
This 12-week, double-blind, placebo-controlled trial will examine whether daily supplementation with the Lab4P probiotic can improve cognitive performance and metabolic health in overweight adults aged 18 to 40 with impaired glucose tolerance, a preclinical condition where blood glucose regulation is mildly disrupted. Seventy participants will be randomly assigned to receive either Lab4P or a placebo. The study will assess changes in memory, executive function, and processing speed, along with blood glucose control, cardiovascular function, cholesterol levels, body composition, and markers of inflammation. The study will also analyse changes in the gut microbiome and evaluate the safety and tolerability of the probiotic.
Eligibility criteria
Qualifiers
Aged 18-40 years
Body Mass Index (BMI) between 25.0 and 29.9 kg/m² (classified as overweight)
In good general health (self-reported)
Normal self-reported sleep patterns, with no history of diagnosed sleep disorders
Disqualifiers
Diagnosed diabetes (any type).
Diagnosed sleep disorders.
Fasting glucose >6.9 mmol/L during screening.
History of bariatric surgery (e.g., gastric bypass, sleeve gastrectomy).
Trial design
Treatments tested in this trial
- Lab4p Probiotic Consortium
- Placebo
Treatment groups
Sponsors and collaborators
Leeds Beckett University
Lead sponsor
Cultech Ltd, Port Talbot, UK
Collaborator